GSM provides services to address the reduction of disease or the risk of disease.  It has designed and implemented a number of IRB-approved trials over the years.  One of its current primary trials focuses on the possible reduction of the risk for cancer.  The origins of the GSM trace back to a previous corporation of the same initials formed in 1990 by Jerome B. Block, M.D., Steven Evans, M.S., and Henry T. Lynch, M.D. as an Omaha-based clinical services corporation.



In 1993, the predecessor company was acquired by and merged into Oncormed, Inc. of Gaithersburg, Maryland, a biotechnology firm providing genetic testing throughout the country. In October of 1998, Gene Logic, Inc. which focused on gene detection, acquired Oncormed. Gene Logic elected to sell the company, which it viewed as extraneous to its core business, back to its original developers, who formed the new and current GSM Company for that purpose.


In 1999, GSM developed a general cancer risk evaluation form, and in conjunction, assessed the nutrition supplements scientific literature to identify those nutritional elements for which there is compelling evidence in the scientific literature to indicate these elements can have a positive effect on those factors associated with cancer risk reduction. The Company designed a 14 ingredient supplement, called Formula #18, which is correlated to the cancer risk questionnaire it developed.  GSM then launched an international clinical trial to evaluate and document the efficacy of this formulation [only available within the Trial].


In 2013, GSM agreed to assemble and distribute the Fukushima Radiation Protection Kit for the Therapeutics Research Institute (TRI) for those individuals who may wish an already-assembled packet.  This service is simply in support of TRI which spearheads and directs this entire effort.